caspase-1 Activators

Nigericin, an ionophore, indirectly activates caspase-1 by triggering potassium efflux. The efflux of potassium activates the NLRP3 inflammasome, leading to the recruitment and activation of caspase-1. Activated caspase-1 then promotes the maturation and release of pro-inflammatory cytokines like IL-1β. Nigericin provides an indirect mechanism for activating caspase-1 in the context of inflammasome activation.

Quercetin, a flavonoid, indirectly modulates caspase-1 by affecting the NLRP3 inflammasome. It inhibits NLRP3 activation and assembly, leading to decreased caspase-1 activation. Additionally, quercetin possesses anti-inflammatory properties, contributing to the suppression of caspase-1-mediated inflammation.

MCC950 is a selective NLRP3 inflammasome inhibitor that indirectly influences caspase-1 activation. By specifically targeting the NLRP3 inflammasome, MCC950 disrupts the assembly and activation of the inflammasome complex, thereby inhibiting the subsequent caspase-1 activation and the release of pro-inflammatory cytokines.

Glyburide, an anti-diabetic drug, indirectly affects caspase-1 by inhibiting the NLRP3 inflammasome. It blocks the ATP-sensitive potassium channel, leading to reduced potassium efflux and subsequent NLRP3 inflammasome activation. This results in the suppression of caspase-1 activation and the associated inflammatory responses.

Bay 11-7082 is an inhibitor of NF-κB activation, indirectly influencing caspase-1 activity. By preventing the activation of NF-κB, Bay 11-7082 downregulates the expression of pro-inflammatory genes, including those involved in the NLRP3 inflammasome pathway. This indirect modulation contributes to the suppression of caspase-1-mediated inflammatory responses.

Bortezomib, a proteasome inhibitor, indirectly influences caspase-1 by modulating NF-κB activation. By inhibiting the proteasome, Bortezomib prevents the degradation of IκBα, leading to the inhibition of NF-κB activation. This indirect effect results in the downregulation of pro-inflammatory genes, including those involved in the NLRP3 inflammasome pathway and caspase-1 activation.

RSL3, an inhibitor of ferroptosis, indirectly affects caspase-1 activation by modulating cellular redox balance. By inducing ferroptosis, RSL3 influences the inflammatory microenvironment, impacting the NLRP3 inflammasome and caspase-1 activation. This provides an indirect mechanism through which RSL3 can influence caspase-1 in the context of cell death and inflammation.